IMR Press / FBL / Volume 29 / Issue 4 / DOI: 10.31083/j.fbl2904137
Open Access Review
Promising Therapeutic Approach in Pancreatic Cancer: Metabolism-Related Genes
Show Less
1 Department of Medical and Biological Sciences, The Catholic University of Korea, 14662 Bucheon, Republic of Korea
2 Department of Biotechnology, The Catholic University of Korea, 14662 Bucheon, Republic of Korea
3 Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
4 Department of Anesthesiology and Pain Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, 06591 Seoul, Republic of Korea
*Correspondence: (Hyun Jung Koh); (Hyunho Yoon)
These authors contributed equally.
Front. Biosci. (Landmark Ed) 2024, 29(4), 137;
Submitted: 1 December 2023 | Revised: 12 March 2024 | Accepted: 19 March 2024 | Published: 2 April 2024
Copyright: © 2024 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Most pancreatic cancers are pancreatic ductal adenocarcinomas. This is an extremely lethal disease with poor prognosis and almost no treatment choices. Considering the profound role of the pancreas in the human body, malfunction of this organ can significantly affect quality of life. Although multiple metabolic pathways are altered in cancer cells, certain metabolic gene signatures may be critical for immunotherapy. The reprogrammed metabolism of glucose, amino acids, and lipids can nourish the tumor microenvironment (TME). Previous studies have also shown that reprogrammed metabolism influences immune responses. Tumor-infiltrating immune cells in the TME can adapt their metabolism to blunt the immune system, leading to immunosuppression and tumor progression. The identification of metabolism-related genes (MRGs) associated with immune reactions in pancreatic cancer may lead to improved treatments. This review highlights the characteristics of MRGs in pancreatic cancer and suggests that enhanced anti-cancer therapies could be used to overcome resistance to immunotherapy.

pancreatic cancer
M2022B002600003/Brain Korea 21
22213MFDS421/Ministry of Food and Drug Safety in Korea
Fig. 1.
Back to top